Current Report Filing (8-k)
03 Août 2022 - 10:06PM
Edgar (US Regulatory)
0001174940
false
0001174940
2022-08-03
2022-08-03
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934.
Date
of Report: August 3, 2022
(Date
of earliest event reported)
Oragenics,
Inc.
(Exact
name of registrant as specified in its charter)
FL |
|
001-32188 |
|
59-3410522 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
Number) |
4902
Eisenhower Boulevard Suite 125,
Tampa,
FL |
|
33634 |
(Address
of principal executive offices) |
|
(Zip
Code) |
813-286-7900
(Registrant’s
telephone number, including area code)
(Former
Name or Former Address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock |
|
OGEN |
|
NYSE
American |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF
CERTAIN OFFICERS.
(e) |
Compensatory
Arrangements of Certain Officers. |
Executive
Officer Equity Awards. On July 29, 2022, the Compensation Committee and Board of Directors approved stock option awards to certain
of our executive officers under the Company’s 2021 Equity Incentive Plan, consisting of an annual grant (“Annual Award”)
to our Chief Financial Officer, Mr. Michael Sullivan and our Senior Vice President of Discovery Research, Dr. Martin Handfield. The Annual
Award is subject to time-based vesting in equal annual installments over a three-year period on the first, second and third anniversaries
of the date of grant, to purchase 200,000 and 100,000 shares of Company common stock, respectively, at an exercise price of $0.3562 per
share, the closing price of the Company’s common stock on the grant date, July 29, 2022. The stock option awards are subject to
the standard terms and conditions of the Company’s form of stock option agreement which includes, as applicable, earlier vesting
upon a change in control of the Company.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits
Exhibit
No. |
|
Description |
|
|
|
104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
In
accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized on this 3rd day of August, 2022.
|
ORAGENICS,
INC. |
|
(Registrant) |
|
|
|
BY: |
/s/
Michael Sullivan |
|
|
Michael
Sullivan |
|
|
Chief
Financial Officer |
Oragenics (AMEX:OGEN)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Oragenics (AMEX:OGEN)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024